Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 930 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cap Clear all
Not listed Phase 3 Interventional

Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults

NCT00008489
View directory record Official record
Conditions
HIV Infections
Interventions
Didanosine
Drug
Lead sponsor
PharmaResearch
Industry
Eligibility
16 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 3:21 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Relationship Between Advanced Glycation Endproducts and Diabetes

NCT02662010
View directory record Official record
Conditions
Diabetic Retinopathy, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 18, 2026, 3:21 PM EDT
Withdrawn Phase 2 Interventional

Antineoplaston Therapy in Treating Patients With Colon Cancer

NCT00003486
View directory record Official record
Conditions
Stage IV Colon Cancer, Recurrent Colon Cancer, Adenocarcinoma of the Colon
Interventions
antineoplaston A10, antineoplaston AS2-1, alternative product therapy, biological therapy, biologically based therapies, cancer prevention intervention, complementary and alternative therapy, differentiation therapy
Drug · Procedure
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet

NCT01287091
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0980, rabeprazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex® Pennkinetic® Extended Release Oral Suspension

NCT00853190
View directory record Official record
Conditions
Healthy
Interventions
Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule, 5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 19, 2016 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 4 Interventional Results available

ABSORICA in Patients With Severe Recalcitrant Nodular Acne

NCT02457520
View directory record Official record
Conditions
Acne
Interventions
Isotretinoin
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
12 Years to 45 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 3 Interventional

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremia

NCT00660959
View directory record Official record
Conditions
Hyponatremia With Normal Extracellular Fluid Volume
Interventions
lixivaptan, placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
38
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetics of Essential Oils in Different Capsules

NCT07581522
View directory record Official record
Conditions
Healthy, Health, Subjective
Interventions
Frankinscense Essential Oil Capsule, Lemon Essential Oil Capsule, Wild Orange Essential Oil Capsule
Other
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 18, 2026, 3:21 PM EDT
Terminated Not applicable Interventional Results available

Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study

NCT03417570
View directory record Official record
Conditions
Barrett Esophagus
Interventions
Esophagogastroduodenoscopy with high definition-white light end endoscopy (HD-WLE) and narrow band imaging (NBI), Olympus Disposable Distal Attachment Cap
Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Results available

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

NCT05027802
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva (FOP)
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
14 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
San Francisco, California • Rochester, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2025 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

NCT00746395
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Lansoprazole 30 mg DR Capsule Fasting Study

NCT01045967
View directory record Official record
Conditions
Healthy
Interventions
Lansoprazole, Prevacid®
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2010 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of SYN-020

NCT04815993
View directory record Official record
Conditions
Enteritis Caused by Radiation (Disorder)
Interventions
SYN-020 delayed release capsule
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Verapamil HCl Extended-Release Capsules 300 mg and Verelan® PM Extended-Release Capsules 300 mg

NCT00648401
View directory record Official record
Conditions
Healthy
Interventions
Verapamil Hydrochloride Extended-Release Capsules, 300 mg, Verelan® PM Extended-Release Capsules, 300 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation

NCT01469819
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Lubiprostone
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 4 Interventional

Single-dose Linaclotide for Capsule Endoscopy Preparation

NCT02465385
View directory record Official record
Conditions
Crohn's, Ulcerative Colitis, Gastrointestinal Bleeding
Interventions
Linaclotide
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 18, 2026, 3:21 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Subjects With Bipolar I Disorder

NCT07540338
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
AL001, Lithium carbonate
Drug
Lead sponsor
Alzamend Neuro, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

NCT05077865
View directory record Official record
Conditions
Hashimoto Disease
Interventions
MYMD-1, Placebo
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

NCT02604992
View directory record Official record
Conditions
Healthy
Interventions
Treatment A, Treatment B, Treatment C
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Results available

A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee

NCT00420992
View directory record Official record
Conditions
Osteoarthritis, Chronic Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
81
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

NCT00601107
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
Doxercalciferol, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Hot Springs, Arizona • Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Oct 18, 2026, 3:21 PM EDT
Withdrawn Not applicable Interventional

Validation of Esophageal Variceal Grading: A Comparative Study of Upper Gastrointestinal (GI) Endoscopy and Capsule Endoscopy

NCT00475592
View directory record Official record
Conditions
Esophageal and Gastric Varices
Interventions
Esophageal Capsule Endoscopy, Upper Gastrointestinal Endoscopy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

NCT01081912
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Placebo, Hydrocodone bitartrate
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
51
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Oct 18, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers

NCT06717269
View directory record Official record
Conditions
Healthy Volunteer
Interventions
NX-5948, Esomeprazole, Placebo, Famotidine, Midazolam, Digoxin, Rosuvastatin, Quinidine
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 18, 2026, 3:21 PM EDT